Drug-drug Interaction of BI 201335 and Microgynon

Phase 1 Completed 16 enrolled Boehringer Ingelheim

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will investigate possible effect of multiple oral doses of BI 201335 on the steady state pharmacokinetics of ethinylestradiol and levonogestrel

Timeline

Start: 2012-04
Primary completion: 2012-08
Completion: 2012-08

Publications

Sabo JP, Lang B, Elgadi M, Huang F. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers. Antimicrob Agents Chemother. 2015 Jan;59(1):514-9. doi: 10.1128/AAC.03589-14. Epub 2014 Nov 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Faldaprevir	Small molecule	240 mg	Oral
Subject	Levonorgestrel	Small molecule	—	Oral
Subject	ethinyl estradiol	Small molecule	—	Oral

Drug-drug Interaction of BI 201335 and Microgynon

Summary

Timeline

Publications

Drugs

Indications